Antibody Fragments Offer Safer Path for Alzheimer's Immunotherapy by Sidestepping ARIA Risks

The UAB-led study in Biomolecules demonstrates that the single-chain variable fragment scFv-h3D6 eliminates MRI-detectable hemorrhages in the APP23 mouse model while preserving Aβ clearance and cognitive benefits, directly contrasting with full-length bapineuzumab. This preclinical work (n=small cohorts typical of transgenic models, experimental rather than RCT) highlights a mechanistic gap missed in the 2025 EMA approvals of lecanemab and donanemab, where ARIA incidence reached 10-27% and was exacerbated by APOEε4. Prior phase 3 bapineuzumab trials (n>2000, halted for lack of efficacy and safety signals) similarly showed vascular leakage tied to Fc-mediated microglial activation across the blood-brain barrier. The fragment approach avoids this recruitment, a pattern also observed in other scFv candidates but rarely tested head-to-head in Alzheimer's models. Limitations include the absence of human data, potential immunogenicity of fragments, and reliance on one transgenic line without long-term dosing. Cross-referencing with the 2023 lecanemab Clarity AD trial (RCT, n=1795) and donanemab TRAILBLAZER-ALZ 2 (RCT, n=1736) underscores that real-world bleeding risks may exceed trial figures once broader populations are treated. No major conflicts reported in the Biomolecules paper, though industry ties to approved antibodies warrant scrutiny in future translation.